Global In Silico Clinical Trial Market 2023-2029
In silico clinical trials refers to the development of patient-specific models to form virtual cohorts for testing the safety and efficacy of new drugs and of new medical devices. Moreover, it could be envisaged that a virtual set of patients could complement a clinical trial (reducing the number of enrolled patients and improving statistical significance), and advise clinical decisions. A chief advantage of in silico clinical trials is the substantial cost savings. The market for in silico clinical trial worldwide is expected to reach USD 4,536 million by 2029, recording a CAGR of 7.5% over the forecast period as per the latest report by Gen Consulting Company.
The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global in silico clinical trial market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches.
This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the therapeutic area, phase, industry, and region. The global market for in silico clinical trial can be segmented by therapeutic area: cardiology, diabetes, infectious diseases, neurology, oncology, others. The oncology segment is estimated to account for the largest share of the global in silico clinical trial market. In silico clinical trial market is further segmented by phase: phase I, phase II, phase III, phase IV. The phase II segment held the largest revenue share in 2022. Based on industry, the in silico clinical trial market is segmented into: medical devices, pharmaceuticals. Globally, the medical devices segment made up the largest share of the in silico clinical trial market. On the basis of region, the in silico clinical trial market also can be divided into: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America. North America was the largest contributor to the global in silico clinical trial market in 2022.
Market Segmentation
By therapeutic area: cardiology, diabetes, infectious diseases, neurology, oncology, others
By phase: phase I, phase II, phase III, phase IV
By industry: medical devices, pharmaceuticals
By region: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America
The report has also analysed the competitive landscape of the global in silico clinical trial market with some of the key players being Abzena Limited, Aganitha AI Inc., Certara, Inc., Codexis Inc., Creative Biolabs, Inc., Dassault Systemes SE, Evotec SE, GNS Healthcare Inc ., Immunetrics Inc., Insilico Biotechnology AG (Yokogawa Electric Corporation), Insilico Medicine Inc., InSilicoTrials Technologies SpA, Instem plc (LeadScope, Inc.), Novadiscovery SAS, Siemens AG, ZMT Zurich MedTech AG, among others. In this report, key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES
Scope of the Report
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook